Mirum Pharmaceuticals (NASDAQ: MIRM) is a late-stage biotechnology company that is making significant progress toward its mission to combat rare diseases with no or limited treatment options. Mirum recently reported its Q1 2026 earnings, headlined by 43% year-over-year (YOY) revenue growth.
In 2025, the company reported revenue of $521.3 million, up 54%, with its lead drug Livmarli responsible for $360 million, a 69% YOY increase. Mirum has two other FDA-approved therapies—Cholbam for bile-acid synthesis disorders, and Ctexli for cerebrotendinous xanthomatosis, a rare genetic bile acid metabolism disorder.
